Hubei Goto Biopharm Group Co., Ltd. (SHE:300966)

Hubei Goto Biopharm Group Revenue

Hubei Goto Biopharm Group had revenue of 168.33M CNY in the quarter ending September 30, 2026, with 10.26% growth. This brings the company's total for the last twelve months to 665.71M, up 6.30% year-over-year. In the year 2025, Hubei Goto Biopharm Group had annual revenue of 606.18M with 12.97% growth. That makes Hubei Goto Biopharm Group the 22,685th largest company in the world by revenue and 4,143rd in China.

• Revenue (ttm): 665.71M
• Revenue Growth: +6.30%
• P/S Ratio: 4.26
• Revenue / Employee: 745.48K
• Employees: 893
• Market Cap: 2.84B

Revenue Chart

Chart

Chart

Revenue by Segment

By Segment

Chart

• Self-Produced 548.18M 90.4%
• Non-Self Produced 58.00M 9.6%

By Geography

Chart

• China 381.67M 63.0%
• Overseas 224.51M 37.0%

Fiscal year ended Dec 31, 2025 See the full Hubei Goto Biopharm Group breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	606.18M	69.58M	12.97%
Dec 31, 2024	536.60M	-29.80M	-5.26%
Dec 31, 2023	566.40M	-38.17M	-6.31%
Jan 1, 2023	604.57M	13.69M	2.32%
Jan 1, 2022	590.89M	122.77M	26.23%

Data Source: S&P Global Market Intelligence Last updated: Oct 26, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Nov 2, 2026

Data Sources Report a data error